The atheromatous lipid core

European Heart Journal

Volumn 19, Issue 1, 1998, Pages 16-18

  Oliver, M F ^a   Davies, M J ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; HUMAN; INTIMA; LIPID METABOLISM; PRIORITY JOURNAL; SHORT SURVEY;

APOPTOSIS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; FOAM CELLS; HUMANS; LIPID METABOLISM; LIPIDS; RUPTURE, SPONTANEOUS;

EID: 0031952706     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0797     Document Type: Short Survey

References (29)

1. [1] Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
2. [2] Fuster V, Badimon JJ. Regression and stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Eur Heart J 1995; 16: 6-12.
3. [3] Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994; 331: 468-9.
4. [4] Libby P. Molecular basis of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
5. [5] Stary HC, Chandler AB, Dinsmore RE, Fuster V et al. A definition of advanced types of atherosclerotic plaque and a histological classification of atherosclerosis. A report from the Committee on Vascular Plaques of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-74.
6. [6] Guyton J, Klemp K. Development of the atherosclerotic core region: chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb 1994; 14: 1305-14.
7. [7] Witztum J. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
8. [8] Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation 1996; 94: 2013-20.
9. [9] Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidised low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. Circulation 1997; 95: 1760-3.
10. [10] Reichl E, Miller NE. Pathophysiology of reverse cholesterol transport: insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis 1989; 9: 785-97.
11. [11] Böttcher CJF, Keppler JG, Ter Haar Romeny-Wachter CC et al. Analysis of the lipids of the arterial wall. Lancet 1958; ii: 1207-9.
12. [12] Smith EB. Intimal and medial lipids in human aortas. Lancet 1960; i: 799-803.
13. [13] Böttcher CJF, Woodford FP, Ter Haar Romeny-Wachter CC et al. Fatty acid distribution in lipids of the arterial wall. Lancet 1960; i: 1378-83.
14. [14] Felton CV, Crook D, Davies MJ Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Atheroscler Throm Vasc Dis 1997; 17: 1337-45.
15. [15] Oliver MF. Perspective of trials of regression of coronary atherosclerosis. Cardiovasc Risk Factors 1992; 2: 234-8.
16. [16] Buchwald H, Varco RL, Matts JP and the POSCH group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990; 323: 946-55.
17. [17] Waters D, Higginson L, Gladstone P et al. Effects of monotherapy with an HMGCoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-68.
18. [18] MAAS Investigators. Effect of simvastatin on coronary atheroma: a multicentre antiatheroma study. Lancet 1994; 334: 633-8.
19. [19] Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS). Circulation 1995; 91: 2528-40.
20. [20] Pitt B, Mancini GBJ, Ellis SG et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133-9.
21. [21] Richardson PD, Davies MJ, Born GVR. Influence on plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; ii: 941-4.
22. [22] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
23. [23] Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
24. [24] Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
25. [25] Egashira K, Hirooka Y, Kai H et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
26. [26] Stroes ESG, Koomans HA, de Bruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-71.
27. [27] Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
28. [28] Felton CV, Crook D, Davies MJ, Oliver MF. Dietary poly-unsaturated fatty acids and composition of human aortic plaques. Lancet 1994; 344: 1195-6.
29. [29] Ridker PM, Cushman M, Stampfer MJ et al. Inflammation aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.